[ad_1] Jean-Jacques Bienaimé, who over the course of nearly two decades grew BioMarin Pharmaceutical’s portfolio from a single commercialized asset to multiple marketed products—including a landmark approval in gene therapy—is…
[ad_1] Jean-Jacques Bienaimé, who over the course of nearly two decades grew BioMarin Pharmaceutical’s portfolio from a single commercialized asset to multiple marketed products—including a landmark approval in gene therapy—is…